natgillin/translations-raw huggingface dataset:
Laropiprant er ikke et substrat af humant P-gp, og derfor forventes andre hæmmere af CYP3A4 og/eller P-gp heller ikke at have en klinisk relevant indvirkning på laropiprants farmakokinetik. 
Laropiprant is not a substrate of human P-gp, and therefore other inhibitors of CYP3A4 and/or P-gp are also not expected to have a clinically meaningful impact on the pharmacokinetics of laropiprant.
• Signifikant eller uforklarlig leverinsufficiens. 
• Significant or unexplained hepatic dysfunction.
Farmakokinetisk steady state opnåedes inden for 2 dage efter dosering én gang dagligt af laropiprant med minimal akkumulation i AUC (ca. 1,3 gange) og Cmax (ca. 1,1 gange). 
Pharmacokinetic steady state is achieved within 2 days of once-daily dosing of laropiprant, with minimal accumulation in AUC (approximately 1.3-fold) and Cmax (approximately 1.1-fold).
• Hurtig eller uregelmæssig hjerterytme (puls) 
• rapid or irregular heartbeat
Det skal De vide, før De begynder at tage Pelzont 
What you need to know before you take Pelzont
Pelzont er indiceret til behandling af dyslipidæmi, især hos voksne patienter med kombineret dyslipidæmi (karakteriseret ved forhøjede koncentrationer af LDL-kolesterol og triglycerider samt lavt HDL-kolesterol) og hos voksne patienter med primær hyperkolesterolæmi (heterozygot familiær og non-familiær). 
Pelzont is indicated for the treatment of dyslipidaemia, particularly in adult patients with combined mixed dyslipidaemia (characterised by elevated levels of LDL-cholesterol and triglycerides and low HDL-cholesterol) and in adult patients with primary hypercholesterolaemia (heterozygous familial and non-familial).
Pædiatrisk population Pelzont: Der er ikke udført undersøgelser med børn. 
Paediatric population Pelzont: No studies have been performed in paediatric patients.
Kosttilskud med nicotinsyre: Vitaminer eller andre ernæringstilskud med (≥ 50 mg /dag) nicotinsyre (eller nicotinamid) er ikke blevet undersøgt sammen med Pelzont. 
Supplements containing nicotinic acid: Vitamins or other nutritional supplements containing (≥ 50 mg/day) of nicotinic acid (or nicotinamide) have not been studied with Pelzont.
Patienter med lever- eller nyreinsufficiens 
Patients with hepatic or renal insufficiency
Skift fra nicotinsyre med umiddelbar udløsning (krystallinsk) til Pelzont er ikke undersøgt. 
Switching from immediate-release (crystalline) nicotinic acid to Pelzont has not been studied.
I disse undersøgelser var procentdelen af patienter, der fik Pelzont, nicotinsyre (depotformuleringer, poolede) eller placebo/simvastatin (poolet), og som stoppede behandlingen på grund af flushing-relaterede symptomer (rødme, varme, kløe og prikken i huden) henholdsvis 7,2 %, 16,6 % og 0,4 %. 
In these studies, the percentage of patients taking Pelzont, nicotinic acid (pooled prolonged-release formulations) or pooled placebo/simvastatin who discontinued due to any flushing-related symptom (redness, warmth, itching and tingling) was 7.2 %, 16.6 %, and 0.4 %, respectively.
• Muskulær toksicitet i anamnesen med statin eller fibrat. 
• Previous history of muscular toxicity with a statin or fibrate
*Inkluderer patienter med moderate, svære eller ekstreme flushing-symptomer 
*Includes patients with moderate, severe, or extreme flushing symptoms †Dose advancement at Week 5
MÆRKNING, DER SKAL ANFØRES PÅ DEN MELLEMSTE EMBALLAGE Multipakninger à 196 (2 pakninger à 98 tabletter med modificeret udløsning) - uden blå boks (til PVC/Aclar blister) 
PARTICULARS TO APPEAR ON THE INTERMEDIATE CARTON Multi-packs of 196 (2 packs of 98 modified-release tablets) - without blue box (for PVC/Aclar blister)
På samme måde som LDL kan også kolesterol- og triglyceridholdige lipoproteiner, inklusive VLDL, intermediate-density lipoproteins (IDL) og rester, fremme aterosklerose. 
Like LDL, cholesterol-enriched triglyceride-rich lipoproteins, including VLDL, intermediate-density lipoproteins (IDL), and remnants, can also promote atherosclerosis.
1'hydroxymidazolam metaboliseres overvejende af uridindiphosphat glucuronosyltransferaserne (UGT) 2B4 og 2B7. 
1'-hydroxymidazolam is metabolised predominantly by uridine diphosphate-glucuronosyltransferases (UGT) 2B4 and 2B7.
I tre store kliniske undersøgelser, hvor patientrapporterede flushing-symptomer blev målt, oplevede de patienter, der tog Pelzont, mindre flushing end de patienter, der tog nicotinsyre (depotformuleringer). 
In three large clinical trials measuring patient-reported flushing symptoms, patients taking Pelzont experienced less flushing than those taking nicotinic acid (prolonged-release formulations).
I den anden undersøgelse (16 uger), hvor acetylsalicylsyre var tilladt, oplevede de patienter, der fik Pelzont, signifikant færre dage pr. uge med moderat eller mere udbredt flushing sammenlignet med nicotinsyre (taget som depotformulering med multi-step titrering fra 500 mg til 2.000 mg over 12 uger) (p < 0,001). 
In the second study (16 weeks) where acetylsalicylic acid was allowed, patients taking Pelzont experienced significantly fewer days per week with moderate or greater flushing compared to nicotinic acid (prolonged-release formulation taken as a 12-week multi-step 500 mg to 2,000 mg titration) (p< 0.001).
MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE YDRE KARTON (til PVC/Aclar blister) 
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON (for PVC/Aclar blister)
Kolesterol er et af flere fedtstoffer i blodet. 
Cholesterol is one of several fats found in your blood.
Nicotinsyre sænker koncentrationen af low-density lipoprotein kolesterol (LDL-C), totalt kolesterol (TC), very low density lipoprotein kolesterol (VLDL-C), apolipoprotein-B (apo-B, det væsentlige LDL-protein) triglycerider (TG) og lipoprotein(a) (Lp(a), en modificeret LDL-partikel) og øger koncentrationen af high-density lipoprotein kolesterol (HDL-C) og apolipoprotein-A-I (apo-A-I, den væsentlige proteinkomponent i HDL). 
Nicotinic acid lowers the levels of low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), very low density lipoprotein cholesterol (VLDL-C), apolipoprotein B (apo B, the major LDL protein), triglycerides (TG), and lipoprotein(a) (Lp(a), a modified LDL particle) and elevates the levels of high-density lipoprotein cholesterol (HDL-C) and apolipoprotein A-I (apo A-I, the major protein component of HDL).
Nicotinsyre: Farmakokinetiske data for ældre (≥ 65 år) er ikke tilgængelige. 
Nicotinic acid: There is no pharmacokinetic data in the elderly (≥ 65 years).
Toksikologiske fund i disse undersøgelser af samtidig administration var i overensstemmelse med de fund, der blev gjort, når nicotinsyre og laropiprant blev administreret enkeltvis. 
Toxicologic findings in these co-administration studies were consistent with those seen with nicotinic acid and laropiprant administered individually.
Der er ikke udført undersøgelser med Pelzont hos diegivende dyr. 
No studies in lactating animals have been conducted with Pelzont.
Der er hyppigt fundet forhøjede TG-koncentrationer i plasma i en triade med lave HDL-C-koncentrationer og små LDLpartikler og også i forbindelse med non-lipide metaboliske risikofaktorer for koronar hjertesygdom. 
Elevated plasma TG levels are frequently found in a triad with low HDL-C levels and small LDL particles, as well as in association with non-lipid metabolic risk factors for coronary heart disease (CHD).
Sjældne tilfælde af myopati/rhabdomyolyse er blevet forbundet med samtidig administration af lipidsænkende doser (≥ 1.000 mg/dag) af nicotinsyre og HMG-CoA-reduktasehæmmere (statiner) (se pkt. 
Rare cases of myopathy/rhabdomyolysis have been associated with concomitant administration of lipid-altering doses (≥ 1,000 mg/day) of nicotinic acid and HMG-CoA reductase inhibitors (statins) (see section 4.8).
I kontrollerede kliniske undersøgelser var incidensen af klinisk relevante stigninger i serumtransaminaser (ALAT og/eller ASAT ≥ 3 x ULN (øvre normalgrænse) konsekutivt) 1,0 % for patienter, der blev behandlet med Pelzont med eller uden et statin. 
In controlled clinical studies, the incidence of clinically important elevations in serum transaminases (ALT and/or AST ≥ 3 X ULN, consecutive) was 1.0 % for patients treated with Pelzont with or without a statin.
kolesterol, fedtholdige stoffer (triglycerider) og apo-B (en del af LDL) i blodet. 
LDL cholesterol, fatty substances called triglycerides and apo B (a part of LDL) in the blood;
Den hepatocellulære centrilobulære hypertrofi var i overensstemmelse med den specifikke enzyminduktion hos gnavere. 
The hepatocellular centrilobular hypertrophy was consistent with rodent specific enzyme induction.
Dette sker ved at sænke den totale mængde af kolesterol, LDL 
It does this by lowering the levels of total cholesterol,
Fertilitet Data fra dyreforsøg er utilstrækkelige med hensyn til indvirkning på fertiliteten (se pkt. 
Fertility Animal studies are insufficient with respect to impairment on fertility (see section 5.3).
HMG-CoA reduktasehæmmere: Når simvastatin kombineredes med nicotinsyre, sås en beskeden stigning i simvastatinsyres (den aktive form af simvastatin) AUC og Cmax, som kan være uden klinisk relevans. 
HMG-CoA reductase inhibitors: When simvastatin is combined with nicotinic acid, a modest increase in AUC and Cmax of simvastatin acid (the active form of simvastatin) was observed, which may be devoid of clinical relevance.
Nicotinsyre 
Nicotinic acid
Der er ingen forskel i nicotinsyres perorale biotilgængelighed hos mænd og kvinder, der får Pelzont. 
There is no difference in the oral bioavailability of nicotinic acid in men and women receiving Pelzont.
Almindelig: stigninger i ALAT og/eller ASAT (konsekutivt, ≥ 3 X ULN), fasteglucose (se nedenfor) Ikke almindelig: stigninger i kreatinkinase (≥ 10 X ULN), LDH, 
Common: elevations in ALT and/or AST (consecutive, ≥ 3 X ULN), fasting glucose (see below) Uncommon: elevations in CK (≥ 10 X ULN), LDH, uric acid (see
Øjne: Cystisk makulært ødem, toksisk amblyopi. 
Eye disorders: Cystoid macular oedema, toxic amblyopia.
• De tidligere har haft leversygdom, gulsot (leversygdom, der medfører gulfarvning af huden og det hvide i øjnene) eller sygdom i lever og galdegang (hepatobiliær sygdom). 
• you have ever had liver disease, jaundice (a liver disorder causing yellowing of the skin and whites of the eyes), or hepatobiliary (liver and bile duct) disease.
Lægen bør overveje indtaget af nicotinsyre fra vitaminer og enæringstilskud, når Pelzont ordineres. 
Physicians should consider the nicotinic acid intake from vitamins and nutritional supplements when prescribing Pelzont.
Nicotinsyre hæmmer frigørelsen af frie fedtsyrer (FFA) fra adipøst væv, som kan bidrage til reduceret plasma LDL-C, TC, VLDL-C, apo-B, TG og Lp(a) samt forhøjet HDL-C og apo-A-I, som alle er forbundet med lavere kardiovaskulær risiko. 
Nicotinic acid inhibits release of free fatty acids (FFA) from adipose tissue, which may contribute to the reduced plasma LDL-C, TC, VLDL-C, apo B, TG, and Lp(a), as well as elevated HDL-C, and apo A-I, all of which are associated with lower cardiovascular risk.
Laropiprant hæmmer PGD2-medieret flushing, som er forbundet med administration af nicotinsyre. 
Laropiprant suppresses PGD2 mediated flushing associated with administration of nicotinic acid.
Pelzont kan anvendes som monoterapi hos patienter, hvor HMG-CoA-reduktasehæmmere anses for at være uhensigtsmæssige eller ikke tåles. 
It can be used as monotherapy only in patients in whom HMG-CoA reductase inhibitors are considered inappropriate or not tolerated.
Pelzont indeholder et sukkerstof, der kaldes lactose. 
Pelzont contains a sugar called lactose.
Gå til lægen regelmæssigt for at følge Deres kolesteroltal, og tal med lægen om målet for Dem. 
Your doctor can measure your cholesterol with a simple blood test. Visit your doctor regularly to keep track of your cholesterol and discuss your goals with your doctor.
Fortæl det også til lægen, hvis De er kineser og tager simvastatin (et statin) eller medicin, der indeholder simvastatin. 
Also tell your doctor if you are taking simvastatin (a statin) or a medicine containing simvastatin and are Chinese.
Hypromellose (E464) Silica, kolloid vandfri (E551) Natriumstearylfumarat Hydroxypropylcellulose (E463) Mikrokrystallinsk cellulose (E460) Croscarmellosenatrium Lactosemonohydrat Magnesiumstearat 
Hypromellose (E464) Colloidal anhydrous silica (E551) Sodium stearyl fumarate Hydroxypropylcellulose (E463) Microcrystalline cellulose (E460) Croscarmellose sodium Lactose monohydrate Magnesium stearate
Patienter med kombineret dyslipidæmi har et højt indhold af det "dårlige" LDL-kolesterol og triglycerider (en slags fedt) i blodet og et lavt indhold af det "gode" HDL-kolesterol. 
Patients with combined mixed dyslipidaemia have high blood levels of ‘bad' LDL cholesterol and triglycerides (a type of fat), and low levels of ‘good' HDL cholesterol.
Ikke almindelig: overfølsomhedsreaktion (se nedenfor) Sjælden: angioødem, type 1-overfølsomhed Ikke kendt: anafylaktisk shock 
Uncommon: hypersensitivity reaction (see below) Rare: angio-oedema; type I hypersensitivity Not known: anaphylactic shock
Forsigtighed bør udvises, når Pelzont administreres sammen med lægemidler, der overvejende metaboliseres af UGT2B4 eller UGT2B7, f.eks. zidovudin. 
Caution should be used when Pelzont is co-administered with medicinal products metabolised predominantly by UGT2B4 or UGT2B7, for instance zidovudine.
Øvrige bivirkninger, der er rapporteret sammen med andre nicotinsyrepræparater Yderligere bivirkninger, som er blevet rapporteret sammen med andre nicotinsyrepræparater (med eller uden statin) ved brug efter markedsføring eller i kliniske studier, omfatter følgende: 
Additional adverse reactions reported with other nicotinic acid medical products Additional adverse reactions that have been reported with other nicotinic acid medicinal products (with or without a statin) in post-marketing use or in clinical trials include the following:
Laropiprant: Administration af laropiprant 40 mg til ikke-dialyserede patienter med svær nyreinsufficiens resulterede ikke i klinisk relevant forandring i laropiprants AUC og Cmax, når man sammenlignede med raske kontrolpersoner. 
Laropiprant: Administration of laropiprant 40 mg in non-dialysed patients with severe renal insufficiency resulted in no clinically meaningful change in the AUC and Cmax of laropiprant, compared to healthy control subjects.
Det Europæiske Lægemiddelagentur har udsat forpligtelsen til at fremlægge resultaterne af studier med Pelzont hos pædiatriske patienter i alderen 7-18 år med heterozygot familiær hyperkolesterolæmi (se pkt. 
The European Medicines Agency has deferred the obligation to submit the results of studies with Pelzont in paediatric patients from 7-18 years old in heterozygous familial hypercholesterolaemia (see section 4.2 for information on paediatric use).
Meget få lægemidler metaboliseres overvejende af UGT2B4 eller UGT2B7. 
Very few medicinal products are known to be metabolised predominantly by UGT2B4 or UGT2B7.
Yderligere analyse viste, at Pelzont (2.000 mg/40 mg) administreret sammen med simvastatin i sammenligning med simvastatin alene øgede apo-A-I signifikant (henholdsvis 8,6 %, 2,3 %) og reducerede Lp(a) signifikant (henholdsvis -19,8 %, 0,0 %). 
Further analysis showed Pelzont (2000 mg/40 mg) co-administered with simvastatin when compared with simvastatin alone significantly increased apo A-I (8.6 %, 2.3 % respectively) and significantly decreased Lp(a) (-19.8 %, 0.0 % respectively ).
Alder har ingen klinisk relevant effekt på nicotinsyres (depotformulering) farmakokinetik på basis af en sammensat analyse af personer i alderen 18-65 år. 
Age has no clinically meaningful effect on pharmacokinetics of nicotinic acid (prolonged-release formulation) based on a composite analysis of subjects ages 18-65 years.
Der er dog set tilfælde af svær levertoksicitet, herunder fulminant levernekrose, hos patienter, som har skiftet fra nicotinsyre med umiddelbar udløsning til langtidsvirkende nicotinsyre-præparater i tilsvarende doser. 
However, cases of severe hepatic toxicity, including fulminant hepatic necrosis, have occurred in patients who have switched from immediate-release nicotinic acid to long-acting nicotinic acid at equivalent doses.
CYP3A4-hæmmer: Clarithromycin (der er en potent hæmmer af CYP3A4 og P-gp) havde ingen klinisk relevant indvirkning på laropiprants farmakokinetik. 
CYP3A4 Inhibitor: Clarithromycin (a potent inhibitor of CYP3A4 and P-gp) did not have a clinically meaningful effect on the pharmacokinetics of laropiprant.
Nicotinsyrens orale biotilgængelighed ændres ikke, når det tages sammen med et måltid med højt fedtindhold. 
The oral bioavailability of nicotinic acid is not altered when it is taken with a high-fat meal.
Unormale laboratorieværdier inkluderede forhøjet amylase og lipase, nedsat hæmatokrit og okkult blod i afføringen. 
Laboratory abnormalities included increased amylase and lipase, decreased haematocrit and occult blood in the stool.
DATO FOR ÆNDRING AF TEKSTEN Yderligere information om Pelzont findes på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu. 
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
Da risikoen for myopati er dosisrelateret, bør Pelzont ikke gives sammen med simvastatin 80 mg eller ezetimibe/simvastatin 10 mg/80 mg til kinesiske patienter. 
Because the risk of myopathy with statins is dose-related, the use of Pelzont with simvastatin 80 mg or ezetimibe/simvastatin 10/80 mg is not recommended in Chinese patients.
• Tør hud 
• dry skin
LDL-kolesterol kaldes ofte det "dårlige" kolesterol, fordi det kan ophobe sig i blodårerne og danne plak. 
LDL cholesterol is often called ‘bad' cholesterol because it can build up in the walls of your arteries and form plaque.
Pelzont bruges som tillæg til diæt for at: 
Pelzont is used in addition to diet
Det er ukendt, om Pelzont går over i modermælken. 
It is not known if Pelzont will pass into your breast milk.
Som andre nicotinsyrepræparater er Pelzont kontraindiceret til patienter med signifikant eller uforklarlig leverinsufficiens. 
Like other nicotinic acid medicinal products, Pelzont is contraindicated in patients with significant or unexplained hepatic dysfunction.
• Prikkende fornemmelse eller følelsesløshed i hænder eller fødder 
• tingling or numbness of the hands or feet
Det er ukendt, om laropiprant udskilles i modermælk. 
It is unknown whether laropiprant is excreted in human breast milk.
Clopidogrel: I en klinisk undersøgelse sås ingen relevant indvirkning af laropiprant på clopidogrels hæmning af ADP-induceret blodpladeaggregation, men der var en beskeden stigning i clopidogrels hæmning af kollagen-induceret blodpladeaggregation. 
Clopidogrel: In a clinical study, there was no meaningful effect of laropiprant on the inhibition of ADP-induced platelet aggregation by clopidogrel, but there was a modest increase in the inhibition of collagen-induced platelet aggregation by clopidogrel.
Denne er karakteriseret ved multiple symptomer, som kan inkludere: Angioødem, pruritus, erythema, paræstesi, bevidsthedstab, opkastning, urticaria, flushing, dyspnø, kvalme, urin- og afføringsinkontinens, koldsved, rysten, kuldegysninger, forhøjet blodtryk, hævede læber, brændende fornemmelse, medicinudslæt, artralgi, hævede ben og takykardi. 
This is characterised by multiple symptoms that may include: angio-oedema, pruritus, erythema, paraesthesia, loss of consciousness, vomiting, urticaria, flushing, dyspnoea, nausea, incontinence of urine and stool, cold sweats, shivering, chills, increased blood pressure, lip swelling, burning sensation, drug eruption, arthralgia, leg swelling, and tachycardia.
Hos raske forsøgspersoner, der fik Pelzont, havde forudgående behandling med acetylsalicylsyre 325 mg ingen yderligere gavnlig effekt på reduktionen af nicotinsyreinducerede flushing-symptomer sammenlignet med Pelzont alene (se pkt. 
In healthy subjects receiving Pelzont, pretreatment with acetylsalicylic acid 325 mg had no additional beneficial effects in reducing nicotinic acid-induced flushing symptoms compared to Pelzont alone (see section 4.8).
De mest almindeligt rapporterede bivirkninger fra forsøgspersoner, der havde fået disse højere doser, svarede til en høj dosis af nicotinsyre og omfattede: Flushing, hovedpine, kløe, kvalme, svimmelhed, opkastning, diarré, epigastrisk og abdominal smerte/ubehag samt rygsmerter. 
The most commonly reported adverse reactions from the subjects who received this higher dose were consistent with a high dose of nicotinic acid and included: flushing, headache, pruritus, nausea, dizziness, vomiting, diarrhoea, epigastric and abdominal pain/discomfort, and back pain.
Hypofosfatæmi 
Hypophosphatemia
Påvirkning af skeletmuskulaturen 
Effect on skeletal muscle
Uigennemsigtig PVC/Aclar blister med push-through aluminiumsfolie, der indeholder 14 tabletter med modificeret udløsning. 
Opaque PVC/Aclar blister with push-through aluminium lidding containing 14 modified-release tablets.
Patienter, der fik MK524A, nicotinsyre (depotformulering) eller placebo, tog også statiner (29 % atorvastatin [5-80 mg], 54 % simvastatin [10-80 mg], 17 % andre statiner [2,5-180 mg] (pravastatin, fluvastatin, rosuvastatin, lovastatin)), hvoraf 9 % også tog ezetimibe [10 mg]. 
Patients receiving Pelzont, nicotinic acid (prolonged-released formulation), or placebo were also taking statins (29 % atorvastatin [5-80 mg], 54 % simvastatin [10-80 mg], 17 % other statins [2.5-180 mg] (pravastatin, fluvastatin, rosuvastatin, lovastatin)), of which 9 % were also taking ezetimibe [10 mg].
• Medicin til at sænke kolesterol kaldet "galdesyrebindende lægemidler", f.eks. colestyramin. 
• medicines used to lower cholesterol called ‘bile acid sequestrants', such as colestyramine.
MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE YDRE KARTON (til Alu/Alublister) 
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON (for Alu/Alu blister)
Der sås klinisk relevante stigninger i kreatinkinase (≥ 10 x ULN) hos 0,3 % af de patienter, der blev behandlet med Pelzont med eller uden et statin (se pkt. 
Clinically important elevations of CK (≥ 10 X ULN) were seen in 0.3 % of the patients treated with Pelzont with or without a statin (see section 4.4).
Symptomerne omfattede besvimelse, kortåndethed, hvæsende vejrtrækning eller besvær med at trække vejret, hævelse af ansigt, læber, tunge samt kløe eller udslæt på huden. 
Symptoms included fainting, shortness of breath, wheezing or trouble breathing, swelling of the face, lips, tongue, itching or hives on the skin.
Der er ingen ændring i nicotinsyres perorale biotilgængelighed med alderen. 
There is no change in the oral bioavailability of nicotinic acid with age.
Plasmakoncentrationen af en af midazolams metabolitter, l'-hydroxymidazolam, steg imidlertid ca. 2 
However, the plasma concentration of a metabolite of midazolam, 1'-hydroxymidazolam, was increased approximately 2-fold with multiple doses of laropiprant.
Ikke almindelig: palpitationer Sjælden: atrieflimren og andre hjertearytmier, takykardi 
Uncommon: palpitations Rare: atrial fibrillation and other cardiac arrhythmias; tachycardia
Pelzont bør anvendes sammen med HMG-CoA reduktasehæmmere (statiner), når den kolesterolsænkende effekt af monoterapi med HMG-CoA-reduktasehæmmere er utilstrækkelig. 
Pelzont should be used in patients in combination with HMG-CoA reductase inhibitors (statins), when the cholesterol lowering effect of HMG-CoA reductase inhibitor monotherapy is inadequate.
• laropiprant, som mindsker rødmen, der er en almindelig bivirkning ved nicotinsyre. 
• laropiprant, which reduces symptoms of flushing, a common side effect of nicotinic acid.
Hver tablet med modificeret udløsning er kapselformet, hvid til off-white, med "552" præget på den ene side. 
What Pelzont looks like and contents of the pack Each modified-release tablet is a capsule-shaped, white to off-white tablet, with “552” debossed on one side.
Som med andre nicotinsyrepræparater er Pelzont blevet forbundet med små fald i fosfor. 
As with other nicotinic acid medicinal products, Pelzont was associated with small decreases in phosphorus levels.